Aroa Biosurgery (ASX:ARX) Short-Term Debt : A$0.00 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Aroa Biosurgery Short-Term Debt?

Aroa Biosurgery's Short-Term Debt for the quarter that ended in Mar. 2024 was A$0.00 Mil.

Aroa Biosurgery's quarterly Short-Term Debt increased from Mar. 2023 (A$0.00 Mil) to Sep. 2023 (A$0.78 Mil) but then declined from Sep. 2023 (A$0.78 Mil) to Mar. 2024 (A$0.00 Mil).

Aroa Biosurgery Short-Term Debt Historical Data

The historical data trend for Aroa Biosurgery's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aroa Biosurgery Short-Term Debt Chart

Aroa Biosurgery Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Mar24

Short-Term Debt

0.82

9.14

Aroa Biosurgery Semi-Annual Data
	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24
Short-Term Debt	Get a 7-Day Free Trial			-	0.49	-	0.78	-

Aroa Biosurgery Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Aroa Biosurgery Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Aroa Biosurgery's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Aroa Biosurgery (ASX:ARX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Aroa Biosurgery Ltd (ASX:ARX) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

64 Richard Pearse Drive, Mangere, Airport Oaks, Auckland, NZL, 2022

Website

https://www.aroabio.com

Aroa Biosurgery Ltd is a soft tissue regeneration company which develops, manufactures and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The Company is in the business of developing, manufacturing and selling soft tissue repair products. The company's principal market is the United States where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery and trauma/limb salvage/tumor surgery.

Aroa Biosurgery (ASX:ARX) Headlines

No Headlines